Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2008 Nov 1.
Published in final edited form as: Bioorg Med Chem Lett. 2007 Aug 25;17(21):5940–5943. doi: 10.1016/j.bmcl.2007.07.103

Synthesis and screening of 3-substituted thioxanthen-9-one-10,10-dioxides

Pedro M J Lory 1, Maria E Estrella-Jimenez 1, Mathew J Shashack 1, Ganesh L Lokesh 1, Amarnath Natarajan 1, Scott R Gilbertson 1,*
PMCID: PMC2040121  NIHMSID: NIHMS32118  PMID: 17826998

Abstract

This manuscript describes methods appropriate for the parallel synthesis of libraries based on the tricyclic thioxanthen-9-one-10,10-dioxide scaffold. The novel compounds were synthesized from previously reported 3-chlorothioxanthen-9-one-10,10-dioxide, and commercially available 3-carboxylic acid thioxanthen-9-one-10,10-dioxide. The library members where screened for activity in a fluorescence polarization assay for inhibitors of BRCT domains of breast cancer gene 1 and in cell-based secreted alkaline phosphatase reported replicon system for activity against hepatitis C virus.


The generation of novel structures amenable to rapid and efficient lead optimization constitutes an important strategy in modern drug discovery. This paper reports the utilization of thioxanthen-9-one-10,10-dioxides as such in structure. Thioxanthenones and thioxanthen-9-one-10,10-dioxides have been shown to possess a number of potentially useful biological activities including anti-tumor,1,2 anti-allergic36 and monoamine oxidase (MAO) inhibitory activity.79 However, some of the most promising drug candidates arising from this class of compounds have shown to have adverse toxic properties in Phase I clinical trials.10,11 Because of the potential demonstrated by this scaffold, an approach to the synthesis of these types of structures utilizing parallel synthesis methods was developed. The molecules synthesized by this approach were screened for their activity in a Hep C replicon assay12 as well as for their ability to inhibit the BRCT(BRCA1)-BACH1 interaction known to have a role in tumor suppression, cell cycle regulation and DNA repair.13

Based on preliminary biological activity data, it was envisioned that introduction of suitably functionalized amino as well as amide derivatives at the 3-position of the thioxanthenone scaffold would not only increase the solubility of this class of compounds but would also retain the postulated pharmacophoric motif required for biological activity. With the goal of synthesizing a small focused library of such molecules, a solution-phase parallel synthesis protocol for the synthesis of 10,10-dioxo-3-piperidin-1-yl/piperizin-1-yl-thioxanthen-9-one 1 as well as 10,10-dioxo-3-carboxamide derivatives 2 (Figure 1) was developed.

Figure 1.

Figure 1

The availability of 3-chloro-10,10-dioxide-thioxanthen-9-one 3 proved to be crucial for the development of a microwave-assisted protocol for the synthesis of a focused library of thirty-six novel 10,10-dioxo-3-piperidin-1-yl/piperizin-1-yl-thioxanthen-9-one derivatives (1).14 Under basic conditions the nucleophilic substitution of thiophenol 3 with the suitably substituted 2-iodo-3-chlorobenzoic acid building block 4 in the presence of a catalytic amount of copper for 8h affords the desired coupled sulfide 5 in virtually quantitative yield (Scheme 1). Treatment of 5 with concentrated sulfuric acid at 100 °C over 4 hours affords the Friedel-Crafts adduct, thioxanthenone 6. Upon pouring the reaction mixture onto ice, the product precipitates out as an off-white solid. Oxidation of 6 with hydrogen peroxide at 90 °C provided the desired sulfone 7, which could be purified by recrystallization from ethyl acetate-hexanes.

Scheme 1.

Scheme 1

Literature precedent for the synthesis of similar amino derivatives requires a multi-step synthesis of the 3-amino substrate followed by appropriate functionalization of the amino moiety or a low yielding acidic hydrolysis of the 3-tetrazole to the corresponding 3-amino product.8 The latter can then be further functionalized only under vigorous basic conditions due to inherent lack of reactivity of the amino functionality.8 The approach reported here makes use of this ring system’s electron-withdrawing properties (carbonyl and sulfone moieties) which allow for efficient aromatic nucleophilic displacement at the 3-chloro position by a variety of commercially available piperidines and piperazines.

Treatment of a solution of 3-chloro-10,10-dioxide-thioxanthen-9-one, in DMF with K2CO3 (1.2 equiv) followed by the addition of the corresponding piperidine or piperazine (1.2 eq.) under microwave conditions lead to the formation of the corresponding 3-piperidin-1-yl/piperizin-1-yl-thioxanthen-9-ones in good to excellent yields (68–99%) (Table 1). Purification of the final products was achieved in a very practical and efficient manner by simple aqueous work-up using citric acid (1M solution) and dichloromethane as extraction solvent. This purification protocol proved equally adaptable to the more basic piperazine products (e.g. 1k–1t), albeit replacement of citric acid by hydrochloric acid (0.5 M solution) was found to be necessary for a more efficient removal of unreacted or slight excess of piperazine. It is also worth noting that this slightly modified acidic work-up resulted in only small amounts of product (<5%) going into the mildly acidic water layer, as monitored by LC-MS. Because of its greater basicity, compound 1k could not be purified by this simple acidic work-up protocol. Instead, it was purified by automated flash chromatography. In some cases within the piperazine series of compounds, and despite the acidic work-up, trace amounts of piperazine (<5%) was found to be present by both 1H NMR and LC-MS analysis.

Table 1.

Synthesis of 10,10-dioxo-3-piperidin-1-yl/piperizin-1-yl-thioxanthen-9-ones.a,b

graphic file with name nihms32118f3.jpg

Yieldb Yieldb Yieldb
graphic file with name nihms32118t1.jpg 1a 68% graphic file with name nihms32118t2.jpg 1m 98% graphic file with name nihms32118t3.jpg 1y 45%d
graphic file with name nihms32118t4.jpg 1b 99% graphic file with name nihms32118t5.jpg 1n 94% graphic file with name nihms32118t6.jpg 1z 49%d
graphic file with name nihms32118t7.jpg 1c 83% graphic file with name nihms32118t8.jpg 1o 80% graphic file with name nihms32118t9.jpg 1aa 45%d
graphic file with name nihms32118t10.jpg 1d 99% graphic file with name nihms32118t11.jpg 1p 82% graphic file with name nihms32118t12.jpg 1bb 57%d
graphic file with name nihms32118t13.jpg 1e 100% graphic file with name nihms32118t14.jpg 1q 70% graphic file with name nihms32118t15.jpg 1cc 82%d
graphic file with name nihms32118t16.jpg 1f 98% graphic file with name nihms32118t17.jpg 1r 88% graphic file with name nihms32118t18.jpg 1dd 18%d
graphic file with name nihms32118t19.jpg 1g 99% graphic file with name nihms32118t20.jpg 1s 98% graphic file with name nihms32118t21.jpg 1ee 40%d
graphic file with name nihms32118t22.jpg 1h 99% graphic file with name nihms32118t23.jpg 1t 98% graphic file with name nihms32118t24.jpg 1ff 6%d
graphic file with name nihms32118t25.jpg 1i 91% graphic file with name nihms32118t26.jpg 1u 87% graphic file with name nihms32118t27.jpg 1gg 40%d
graphic file with name nihms32118t28.jpg 1j 93% graphic file with name nihms32118t29.jpg 1v 47%d graphic file with name nihms32118t30.jpg 1hh 76%d
graphic file with name nihms32118t31.jpg 1k 72%c graphic file with name nihms32118t32.jpg 1w 25%d graphic file with name nihms32118t33.jpg 1ii 12%d
graphic file with name nihms32118t34.jpg 1l 73% graphic file with name nihms32118t35.jpg 1x 30%d graphic file with name nihms32118t36.jpg 1jj 74%d
a

Reactions were run using chloro-sulfone 7, 1.2 equiv. of amine and 1.2 equiv. of K2CO3 and 6.0 mL of solvent in a CEM Discovery microwave system. A microwave irradiation power of 300W, ramp time of 2.0 min. with a run time of 30 min. at 155°C and simultaneous cooling (powermax mode) was used.

b

Unless noted isolated crude yields are reported.

c

2.2 equiv. of K2CO3 were used for the synthesis of this product.

d

Isolated yields after column chromatography.

Given the general good yields at which these reactions proceed, screening of alternative reaction conditions was not actively pursued. Primary amines such as isopropyl amine, benzylamine, 4-(2-aminoethyl)morpholine and cyclopenthyl amine were examined. In all cases the expected products were presented in reaction mixtures as judged by LC-MS and proton NMR but further purification was required.

Taking advantage of the commercially available 9-oxo-9H-thioxanthene-3-carboxylic acid 10,10-dioxide (8) a small number of 3-substituted carboxylamides thioxanthen-9-one-10,10-dioxide 9 (9a–9k) were synthesized. Substituted carboxylic amides at the 3-position of the thioxanthen-9-one-10,10-dioxide have been reported to be selective inhibitors of monoamine oxidases.4 Although Harfenist M. et. al. have reported the synthesis of various 3- substituted carboxylamides thioxanthen-9-one 10,10-dioxide from the acid chloride derived from the 3-substituted carboxylic acid, we opted to use coupling reagents to synthesize the desired amides. Several common coupling reagents, bases and solvents were screened, ranging from polymer-supported reagents such as PS-piperidinomethyl as base as well as PS-DCC as coupling reagent. Ultimately, the best results were obtained using diisopropylethylamine (DIPEA) as base, methylene chloride or DMF as solvents and BOP or HBTU as coupling reagents. With methylene chloride generally being the preferred solvent. In both cases, using either BOP or HBTU, automated flash chromatography was employed in the purification of the desired amides (Table 2).

Table 2.

Synthesis of 10,10-dioxo-3-carboxamides-thioxanthen-9-ones.a

graphic file with name nihms32118f4.jpg

R Product Yieldb R Product Yieldb
graphic file with name nihms32118t37.jpg 9a 36% graphic file with name nihms32118t38.jpg 9g 29%
graphic file with name nihms32118t39.jpg 9b 46% graphic file with name nihms32118t40.jpg 9h 67%
graphic file with name nihms32118t41.jpg 9c 24% graphic file with name nihms32118t42.jpg 9i 57%
graphic file with name nihms32118t43.jpg 9d 30% graphic file with name nihms32118t44.jpg 9j 56%
graphic file with name nihms32118t45.jpg 9e 31% graphic file with name nihms32118t46.jpg 9k 71%
graphic file with name nihms32118t47.jpg 9f 66%
a

Reactions were run using carboxylic acid-sulfone 8, 1.1 equiv. of amine, 1.1 equiv. of HBTU or BOP and 5.0 equiv. of DIPEA (Diisopropylethyl amine) in 5.0 mL of solvent (CH2Cl2) at RT.

b

Isolated crude yields are reported.

The compounds where screened for activity in a cell-based secreted alkaline phosphatase reported replicon system for activity against hepatitis C assay12 and a fluorescence polarization assay for inhibition of the BRCT-BACH1 interaction.13

In the case of the hepatitis C replicon system no significant activity was observed. While in the BRCT-BACH1 assay system three compounds 1h, 1i and 1b exhibited moderate Ki values 38 ± 1, 30 ± 6 and 39 ±3 μMol respectively. We are currently synthesizing bifunctional versions of these molecules for further testing in the BRCT-BACH1 system.

In summary, a focused library of 3-substituted thioxanthenones was synthesized by the facile nucleophilic aromatic substitution and amide bond formation. In general, this reaction was found to work well with secondary amines providing products in greater than or equal to 90% purity after simple extraction. A small collection of amides was also obtained in comparable purity from the HBTU or BOP coupling of the corresponding acid with an amine. All of the synthesized compounds where screened for biological activity in two different assays with three compounds providing moderate inhibition of the BRCT-BACH1 protein-protein interaction.

Supplementary Material

01

Acknowledgments

This work was supported by NIH P41 GM079588. Financial assistance provided by the Robert A. Welch foundation is gratefully acknowledged. M.E.E-J. acknowledges support by a training fellowship from the Keck Center Pharmacoinformatics Training Program of the Gulf Coast Consortia (NIH Grant # T90DK071504-03)

Footnotes

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

References

  • 1.Azuine MA, Tokuda H, Takayasu J, Enjyo F, Mukainaka T, Konoshima T, Nishino H, Kapadia GJ. Pharmacol Res. 2004:49. doi: 10.1016/j.phrs.2003.07.014. [DOI] [PubMed] [Google Scholar]
  • 2.Kostakis IK, Pouli N, Marakos P, Mikros E, Skaltsounis AL, Leonce S, Atassi G, Renard P. Bioorg Med Chem. 2001;9:2793–2802. doi: 10.1016/s0968-0896(01)00130-4. [DOI] [PubMed] [Google Scholar]
  • 3.Cragoe EJ, Jr, Rooney CS, Rokach J. Application: EP EP. Merck and Co., Inc., USA: Merck Frosst Canada, Inc; 1985. p. 77. [Google Scholar]
  • 4.Rokach J, Rooney CS, Cragoe EJ. US Patent. 1985;4507 [Google Scholar]; (b) Rokach J, Rooney CS, Cragoe EJ. 1985 US. [Google Scholar]
  • 5.Batchelor JF. Application: AU AU. Wellcome Foundation Ltd; Australia: 1982. p. 46. [Google Scholar]
  • 6.Hodson HF, Batchelor JF. Application: US US. Burroughs Wellcome Co; USA: 1978. p. 14. [Google Scholar]
  • 7.Harfenist M, Heuser DJ, Joyner CT, Batchelor JF, White HL. J Med Chem. 1996;39:1857–1863. doi: 10.1021/jm950595m. [DOI] [PubMed] [Google Scholar]
  • 8.Harfenist M, Joyner CT, Mize PD, White HL. J Med Chem. 1994;37:2085–2089. doi: 10.1021/jm00039a021. [DOI] [PubMed] [Google Scholar]
  • 9.Harfenist M, Joseph DM, Spence SC, Mcgee DP, Reeves MD, White HL. J Med Chem. 1997;40:2466–2473. doi: 10.1021/jm9608063. [DOI] [PubMed] [Google Scholar]
  • 10.LoRusso PM, Foster BJ, Wozniak A, Heilbrun LK, McCormick JI, Ruble PE, Graham MA, Purvis J, Rake J, Drozd M, Lockwood GF, Corbett TH. Clinical Cancer Research. 2000;6:3088–3094. [PubMed] [Google Scholar]
  • 11.Stevenson JP, DeMaria D, Reilly D, Purvis JD, Graham MA, Lockwood G, Drozd M, O’Dwyer PJ. Cancer Chemother Pharmacol. 1999;44:228–234. doi: 10.1007/s002800050971. [DOI] [PubMed] [Google Scholar]
  • 12.Bourne N, Pyles RB, Yi M, Veselenak RL, Davis MM, Lemon SM. Antiviral Resarch. 2005;67:76–82. doi: 10.1016/j.antiviral.2005.03.006. [DOI] [PubMed] [Google Scholar]
  • 13.Lokesh GL, Rachamallu A, Kishore Kumar GD, Natarajan A. Anal Biochem. 2006;352:135–138. doi: 10.1016/j.ab.2006.01.025. [DOI] [PubMed] [Google Scholar]
  • 14.Lory PMJ, Agarkov A, Gilbertson S. R Synlett. 2006:3045–3048. [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

01

RESOURCES